Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ANTI-3-18F-FACBC IN COMPARISON TO 11C-CHOLINE PET/CT IN THE EVALUATION OF PATIENTS WITH SUSPECT PROSTATE CANCER RELAPSE [ANTI-3-18F-FACBC (anti1-amino-3-18F-fluorocyclobutane-1-carbossilico) rispetto alla 11C-colina PET / TC nella valutazione dei pazienti con sospetta ripresa di carcinoma prostatico]

Trial Profile

ANTI-3-18F-FACBC IN COMPARISON TO 11C-CHOLINE PET/CT IN THE EVALUATION OF PATIENTS WITH SUSPECT PROSTATE CANCER RELAPSE [ANTI-3-18F-FACBC (anti1-amino-3-18F-fluorocyclobutane-1-carbossilico) rispetto alla 11C-colina PET / TC nella valutazione dei pazienti con sospetta ripresa di carcinoma prostatico]

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fluciclovine 18F (Primary)
  • Indications Prostate cancer
  • Focus Diagnostic use
  • Most Recent Events

    • 15 Mar 2016 Status changed from recruiting to completed, according to results presented at the 31st Congress of the European Association of Urology.
    • 30 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top